

Positions

Access

- [Access to healthcare \(PDF 0.3 MB\)](#)
- [Value-Based Healthcare \(PDF 0.1 MB\)](#)

R&D

- [Animal research \(PDF 0.2 MB\)](#)
- [Clinical study transparency \(PDF 0.2 MB\)](#)
- [Medicines for Patients with Rare Diseases \(PDF 0.2 MB\)](#)
- [Post-trial Access \(PDF 0.1 MB\)](#)
- [Novartis Position on Access to Unauthorized Novartis Products through Managed Access Programs \(MAPs\) \(PDF 0.2 MB\)](#)
- [Responsible Clinical Trials \(PDF 0.1 MB\)](#)
- [Novartis Commitment to Diversity in Clinical Trials \(PDF 0.2 MB\)](#)
- [Novartis Position on Investigator Initiated Trials \(IITs\) and Investigator Initiated Research \(IIRs\) \(PDF 0.2 MB\)](#)
- [Position on Scientific Publications \(PDF 0.2 MB\)](#)

Quality and safety of medicines

- [Falsified Medical Products \(PDF 0.3 MB\)](#)

Intellectual property

- [Intellectual Property \(PDF 0.3 MB\)](#)
- [Regulatory data protection \(PDF 0.3 MB\)](#)

Ethics

- [Novartis Position on Collaborating with Patient Organizations \(PDF 0.2 MB\)](#)

Biologics

- [Innovative Biologic Medicines and Biosimilars \(PDF 0.1 MB\)](#)

Environment

- [Pharmaceuticals in the environment \(PDF 0.2 MB\)](#)

Taxation

- [Novartis Tax Policy Statement \(PDF 0.2 MB\)](#)

Source URL: <https://www.novartis.com/node/639291>

List of links present in page

1. <https://www.novartis.com/node/639291>
2. https://www.novartis.com/sites/novartis_com/files/access-to-healthcare-perspective.pdf
3. https://www.novartis.com/sites/novartis_com/files/novartis-position-on-value-based-healthcare.pdf
4. https://www.novartis.com/sites/novartis_com/files/animal-research.pdf
5. https://www.novartis.com/sites/novartis_com/files/clinical-trial-data-transparency.pdf
6. https://www.novartis.com/sites/novartis_com/files/medicines-for-patients-with-rare-diseases.pdf
7. https://www.novartis.com/sites/novartis_com/files/novartis-position-on-post-trial-access.pdf
8. https://www.novartis.com/sites/novartis_com/files/novartis-position-unauthorized-products-access.pdf
9. https://www.novartis.com/sites/novartis_com/files/novartis-position-on-responsible-clinical-trials.pdf
10. https://www.novartis.com/sites/novartis_com/files/commitment-for-diversity-in-clinical-trials.pdf

11. https://www.novartis.com/sites/novartis_com/files/novartis-investigator-initiated-trials.pdf
12. https://www.novartis.com/sites/novartis_com/files/position-on-scientific-publications.pdf
13. https://www.novartis.com/sites/novartis_com/files/novartis-position-on-falsified-medical-products.pdf
14. https://www.novartis.com/sites/novartis_com/files/novartis-intellectual-property-position.pdf
15. https://www.novartis.com/sites/novartis_com/files/regulatory-data-protection.pdf
16. https://www.novartis.com/sites/novartis_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf
17. https://www.novartis.com/sites/novartis_com/files/biosimilars-key-regulatory-and-market-access-aspects.pdf
18. https://www.novartis.com/sites/novartis_com/files/pharmaceuticals-environment.pdf
19. https://www.novartis.com/sites/novartis_com/files/tax-policy-statement.pdf
20. <https://www.novartis.com/node/639291/printable/print>
21. <https://www.novartis.com/node/639291/printable/pdf>